Coloplast A/S (COLO-B)
Copenhagen Exchange · Denmark · prices in DKK · close of 22 Oct 2026
Key indicators
| Last close | DKK 479.10 |
|---|---|
| 52-week range | 369.70 – 631.40 |
| Return, 1 month / 3 months | +13.9% / +16.3% |
| Return, 1 year / 3 years | −16.9% / −27.6% |
| Trend | Uptrend |
| RSI (14) | 71 |
| Volatility (1 year) | 28.0% |
| Worst drawdown (1 year) | -36.7% |
| Average daily value traded | 146.24M DKK |
| Dividend yield | 4.8% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Coloplast A/S is a Danish medical device company that develops and makes products for people with intimate healthcare needs. Its range covers ostomy care, with stoma bags and skin barriers, and continence care, including catheters and urine collection products. It also supplies wound and skin care items and products for voice and respiratory care. Customers are mainly hospitals, clinics and home-care users, and the company is based in Denmark and serves markets around the world.
Coloplast A/S trades under the code COLO-B on the Copenhagen Exchange in Denmark, with its price quoted in Danish kroner (DKK). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Coloplast A/S (COLO-B) trades on the Copenhagen Exchange in Denmark. It last closed at DKK 479.10 on 22 October 2026.
Its price-based Market X-Ray is 61 out of 100 (a fair price profile), ranking 60 of 164 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 16.9% and over the last three months it rose 16.3%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Copenhagen Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 50 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 9.2% | ||
| From 52-week high | -22.1% | ||
| Momentum | 59 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 16.3% | ||
| 6-month return | 14.6% | ||
| 12-month return, skipping the last month | -27.1% | ||
| Stability (higher is calmer) | 44 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 28.0% | ||
| Worst drawdown, 1 year (smaller is calmer) | -36.7% | ||
| Liquidity | 94 · Strong | Trades actively. | |
| Average daily value traded | 146.24M DKK | ||
| Zero-volume days | 0.0% | ||
| Income | 89 · Strong | Dividend is high and has been paid regularly. | |
| Dividend yield | 4.8% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
- Income: Dividend is high and has been paid regularly.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
Returns
| 1 week | +2.3% |
|---|---|
| 1 month | +13.9% |
| 3 months | +16.3% |
| 6 months | +14.6% |
| 1 year | −16.9% |
| 3 years | −27.6% |
| 5 years | −47.9% |
Signals
| 50-day / 200-day average | 439.99 / 438.93 |
|---|---|
| Golden / death cross (60 days) | Golden, 0 days ago |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 10.14 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 18 May 2026 | DKK 5.0000 |
| 5 Dec 2025 | DKK 18.0000 |
| 8 May 2025 | DKK 5.0000 |
| 6 Dec 2024 | DKK 17.0000 |
| 13 May 2024 | DKK 5.0000 |
| 8 Dec 2023 | DKK 16.0000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Copenhagen Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.